In vitro activity: Pleconaril (also known as VP 63843; Win 63843) is a capsid inhibitor and an antiviral drug that has the potential for the treatment of enterovirus infection and asthma. Pleconaril is effective in inhibiting replication with an IC50 of 50 nM. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus.It has shown useful activity against the dangerous strain enterovirus D68. Pleconaril has been used as treatment on a compassionateuse basis in neonates and immunodeficient patients with severe EV infections.

Kinase Assay: Pleconaril (also known as VP 63843; Win 63843) is a capsid inhibitor and an antiviral drug that has the potential for the treatment of enterovirus infection and asthma. Pleconaril is effective in inhibiting replication with an IC50 of 50 nM.

Cell Assay: Rhinovirus infections do not only cause common colds, but may also trigger severe exacerbations of asthma and chronic obstructive pulmonary disease (COPD). Even though rhinoviruses have been the focus of extensive drug development efforts in the past, an anti-rhinoviral drug still has to make it to the market. In the past, the viral capsid protein VP1 has been shown to be an important target for the development of antiviral molecules. Furthermore, many different chemical scaffolds appear to possess the properties that are required to inhibit virus replication by this mechanism of action. I-6602, an analogue of the rhinovirus inhibitor pirodavir, was previously identified as a potent inhibitor of rhinovirus infection. Here, we describe the antiviral activity of its analogue ca603, a molecule with a modified linker structure, and corroborate its mechanism of action as a capsid binder.